These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 30819472)

  • 1. Association of Complete Radiologic and Pathologic Response following Locoregional Therapy before Liver Transplantation with Long-Term Outcomes of Hepatocellular Carcinoma: A Retrospective Study.
    Habibollahi P; Shamchi SP; Choi JM; Gade TP; Stavropoulos SW; Hunt SJ; Dagli M; Sudheendra D; Mondschein JI; Soulen MC; Nadolski GJ
    J Vasc Interv Radiol; 2019 Mar; 30(3):323-329. PubMed ID: 30819472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Locoregional Therapy of Hepatocellular-Cholangiocarcinoma versus Hepatocellular Carcinoma: A Propensity Score-Matched Study.
    Huang YH; Park BV; Chen YF; Gaba RC; Guzman G; Lokken RP
    J Vasc Interv Radiol; 2019 Sep; 30(9):1317-1324. PubMed ID: 31375450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiologic-histological correlation of hepatocellular carcinoma treated via pre-liver transplant locoregional therapies.
    El-Gazzaz G; Sourianarayanane A; Menon KV; Sanabria J; Hashimoto K; Quintini C; Kelly D; Eghtesad B; Miller C; Fung J; Aucejo F
    Hepatobiliary Pancreat Dis Int; 2013 Feb; 12(1):34-41. PubMed ID: 23392796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to Loco-Regional Therapy Predicts Outcomes After Liver Transplantation for Combined Hepatocellular-Cholangiocarcinoma.
    Antwi SO; Habboush YY; Chase LA; Lee DD; Patel T
    Ann Hepatol; 2018 Oct; 17(6):969-979. PubMed ID: 30600299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology.
    Gordic S; Corcuera-Solano I; Stueck A; Besa C; Argiriadi P; Guniganti P; King M; Kihira S; Babb J; Thung S; Taouli B
    J Hepatol; 2017 Dec; 67(6):1213-1221. PubMed ID: 28823713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
    Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
    J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria.
    Kardashian A; Florman SS; Haydel B; Ruiz RM; Klintmalm GB; Lee DD; Taner CB; Aucejo F; Tevar AD; Humar A; Verna EC; Halazun KJ; Chapman WC; Vachharajani N; Hoteit M; Levine MH; Nguyen MH; Melcher ML; Langnas AN; Carney CA; Mobley C; Ghobrial M; Amundsen B; Markmann JF; Sudan DL; Jones CM; Berumen J; Hemming AW; Hong JC; Kim J; Zimmerman MA; Nydam TL; Rana A; Kueht ML; Fishbein TM; Markovic D; Busuttil RW; Agopian VG
    Hepatology; 2020 Dec; 72(6):2014-2028. PubMed ID: 32124453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of locoregional therapy before living donor liver transplantation in patients with hepatocellular carcinoma who meet the Milan criteria.
    Kim JM; Kwon CH; Joh JW; Choi MS; Lee JH; Koh KC; Paik SW; Kim GS; Kim SJ; Lee SK; Yoo BC
    Transplant Proc; 2012 Mar; 44(2):403-8. PubMed ID: 22410028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium.
    Mehta N; Frenette C; Tabrizian P; Hoteit M; Guy J; Parikh N; Ghaziani TT; Dhanasekaran R; Dodge JL; Natarajan B; Holzner ML; Frankul L; Chan W; Fobar A; Florman S; Yao FY
    Gastroenterology; 2021 Nov; 161(5):1502-1512. PubMed ID: 34331914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transarterial Chemoembolization Followed by Radiofrequency Ablation for Hepatocellular Carcinoma: Impact of the Time Interval between the Two Treatments on Outcome.
    Liu D; Liu M; Su L; Wang Y; Zhang X; Long H; Kuang M; Xie X; Lin M
    J Vasc Interv Radiol; 2019 Dec; 30(12):1879-1886. PubMed ID: 31669087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete pathologic response to pretransplant locoregional therapy for hepatocellular carcinoma defines cancer cure after liver transplantation: analysis of 501 consecutively treated patients.
    Agopian VG; Morshedi MM; McWilliams J; Harlander-Locke MP; Markovic D; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Hiatt JR; Busuttil RW
    Ann Surg; 2015 Sep; 262(3):536-45; discussion 543-5. PubMed ID: 26258323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bridging Hepatocellular Carcinoma to Transplant: Transarterial Chemoembolization Response, Tumor Biology, and Recurrence after Transplantation in a 12-Year Transplant Cohort.
    Sandow T; Pavlus J; Field D; Lacayo E; Cohen E; Lynskey G; Caridi T; Buckley D; Cardella J; Kallakury B; Spies J; Kim AY
    J Vasc Interv Radiol; 2019 Jul; 30(7):995-1003. PubMed ID: 31109853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bridging Locoregional Therapy Prolongs Survival in Patients Listed for Liver Transplant with Hepatocellular Carcinoma.
    Xing M; Sakaria S; Dhanasekaran R; Parekh S; Spivey J; Knechtle SJ; Zhang D; Kim HS
    Cardiovasc Intervent Radiol; 2017 Mar; 40(3):410-420. PubMed ID: 27900445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-liver transplantation locoregional adjuvant therapy for hepatocellular carcinoma as a strategy to improve longterm survival.
    Bharat A; Brown DB; Crippin JS; Gould JE; Lowell JA; Shenoy S; Desai NM; Chapman WC
    J Am Coll Surg; 2006 Oct; 203(4):411-20. PubMed ID: 17000383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocellular Carcinoma Progression While on Waiting List for Liver Transplantation.
    Giacomoni A; Concone G; Di Sandro S; Lauterio A; De Carlis L
    Transplantation; 2015 Sep; 99(9):e155-6. PubMed ID: 26308419
    [No Abstract]   [Full Text] [Related]  

  • 16. Locoregional Therapies for Hepatocellular Carcinoma prior to Liver Transplant: Comparative Pathologic Necrosis, Radiologic Response, and Recurrence.
    Mosenthal M; Adams W; Cotler S; Ding X; Borge M; Malamis A; Lee D; Thomas T; Jawahar A; Amin P; Molvar C
    J Vasc Interv Radiol; 2024 Apr; 35(4):506-514. PubMed ID: 38123127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoembolization Combined with Radiofrequency Ablation for Medium-Sized Hepatocellular Carcinoma: A Propensity-Score Analysis.
    Chu HH; Kim JH; Yoon HK; Ko HK; Gwon DI; Kim PN; Sung KB; Ko GY; Kim SY; Park SH
    J Vasc Interv Radiol; 2019 Oct; 30(10):1533-1543. PubMed ID: 31471190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Locoregional Therapy and Predictors for Dropout in Patients with Hepatocellular Carcinoma Listed for Liver Transplantation.
    Sheth RA; Patel MS; Koottappillil B; Shah JA; Oklu R; Mueller P; Vagefi PA; Ganguli S
    J Vasc Interv Radiol; 2015 Dec; 26(12):1761-8; quiz 1768. PubMed ID: 26419427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver Imaging-Reporting and Data System treatment response algorithm predicts postsurgical recurrence in locoregional therapy-treated hepatocellular carcinoma.
    Youn SY; Kim B; Kim DH; Choi HJ; Sung PS; Choi JI
    Eur Radiol; 2022 Sep; 32(9):6270-6280. PubMed ID: 35348864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conventional Chemoembolization Plus Radiofrequency Ablation versus Surgical Resection for Single, Medium-Sized Hepatocellular Carcinoma: Propensity-Score Matching Analysis.
    Lee HJ; Kim JW; Hur YH; Cho SB; Lee BC; Lee BK; Hwang EC; Cho YS; Seon HJ
    J Vasc Interv Radiol; 2019 Mar; 30(3):284-292.e1. PubMed ID: 30819467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.